Σημειώσεις επεισοδίου
References:
Cheung T. COMPASS Announces Positive Outcome of 25 mg COMP360 Psilocybin Therapy as Adjunct to SSRI Anti-depressant in Open-Label, Treatment-Resistant Depression Study. COMPASS Health. 13 Dec 2021 [press release].
Grinspoon P. The Popularity of Microdosing of Psychedelics: What Does the Science Say? Harvard Health. 19 Sept 2022.
Gukasyan N, et al. Attenuation of Psilocybin Mushroom Effects During and After SSRI/SNRI Anti-depressant Use. Sage Journals. 2023 Jul; 37(7): 707-716
Malcolm B and Thomas K. Serotonin Toxicity of Serotonergic Psychedelics. Psychopharmacology. 2022;239…
Ιστότοπος: neuralpharm.substack.com

